MADRID, 26 Mar. (EUROPA PRESS) -

PharmaMar has increased its treasury stock to 4.37% of the group's capital, from the previous 3.553%, which represents a historical maximum since there are records, according to the information sent this Tuesday to the National Securities Market Commission (CNMV).

This operation has occurred after the completion of its share buyback program at the end of January, which had a maximum extension of six months and concluded with the acquisition of 2.28% of its share capital, that is, a total of 419,400 own titles.

The share acquisition or transfer operations dated January 30, 2024, of 659 shares and February 20, 2024, of 20 shares, correspond to operations carried out directly by PharmaMar or indirectly by the group companies, within the framework of the free share delivery plans approved by the company.

Likewise, the company, direct owner of 100% of the share capital of Sylentis and Genómica, has detailed that Sylentis is the owner of 284 shares of PharmamMar and Genómica, of 115 shares, both as a consequence of the voluntary resignation of some of its employees and in implementation of group delivery plans.

PharmaMar closed 2023 with a net profit of 1.14 million euros, which represents a decrease of almost 98% compared to the previous year, when it earned 49.36 million euros.

The company recorded total revenues of 158.15 million euros, 19.45% less, due to the impact of the arrival of the generic trabectedin to the European market.